StockData

Artiva Biotherapeutics vs aTYR PHARMA

ARTV and ATYR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARTV and ATYR compare

aTYR PHARMA is the larger company, worth 2.6 times as much as Artiva Biotherapeutics ($489M against $189M).

Artiva Biotherapeutics scores higher on the StockData Score (8 against 5 for aTYR PHARMA), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARTVATYR
Size and price
Market cap$189M$489M
Share price$3.86$4.99
Change, 1 year18.8%563%
Change, 5 years–−98.5%
Beta (5Y)4.84–
Employees10458
StockData Score
Total score8 (better)5
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/B0.5× (better)10.0×
FCF yield−40.8%−11.2% (better)
Growth
Revenue growth, 5Y average–−55.1%
Profitability
Return on equity−36.6% (better)−98.4%
Return on invested capital−3203%–
Financial health
Debt / equity0.000.00
Current ratio24.16 (better)5.12
Altman Z-score4.16 (better)−0.96
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions83.2%41.4%
Held by insiders68.3%2.6%
Insider net buying, 12 months$106M (better)$43.7K
Superinvestors holding1–
Short interest, % of float19.0%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.